Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- New PIII Breast Cancer Trial Kicks Off for Daiichi’s HER3 ADC
August 29, 2025
- Sanofi Files for Subcutaneous Formulation of Sarclisa in Japan
August 29, 2025
- BeOne’s Tevimbra Could Stand Apart in PD-1 Class with Unique Feature: Expert
August 28, 2025
- Sawai to Raise Awareness for Launch of Alcoholism Therapy App HAUDY
August 28, 2025
- Meiji Breaks Ground on “Dual-Use” Plant for Antibiotics and Vaccines
August 28, 2025
- Nihon Chouzai Shuts Down FINDAT Formulary Biz amid Tepid Demand
August 28, 2025
- Amicus’ Pompe Disease Drugs Hit Japan Market
August 28, 2025
- LP.8.1-Tailored Nuvaxovid COVID Jab Approved in Japan: Takeda
August 28, 2025
- Kringle, Keio Pair Up on HGF Therapy for Peripheral Nerve Injury
August 27, 2025
- ASKA Presses Dalton for Transparency on 30% Stake Plan
August 26, 2025
- Meiji Revives Penicillin Raw Material Production in Japan after 31 Years, Races to Pass Down Know-How
August 26, 2025
- Nippon Kayaku to Set Up Singapore-Based JV to License Drugs in Asia
August 26, 2025
- Dayvigo, Jardiance Heavily Promoted in July: Intage
August 26, 2025
- Japan Approves Roche Diagnostics Test for HER2 Ultralow Breast Cancer
August 26, 2025
- Daiichi Sankyo’s TROP2 ADC Datroway Approved in China
August 26, 2025
- Austria, Germany Become First EU Markets to Launch Leqembi
August 26, 2025
- Astellas CFO Outlines Cost Cuts, Licensing Push as Xtandi Nears Patent Cliff
August 25, 2025
- Meiji’s Rezurock Approved in Thailand
August 25, 2025
- Linepharma Japan Eyes Ophthalmology as Second Pillar to Women’s Health
August 22, 2025
- Sanofi Begins Japan PII for Type 1 Diabetes Med Teplizumab
August 22, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…